2,3-bis(3'-hydroxybenzyl)butyrolactone has been researched along with Chronic Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eichholzer, M; Linseisen, J; Nicastro, HL; Platz, EA; Richard, A; Rohrmann, S | 1 |
| Adlercreutz, H; Kilkkinen, A; Klaukka, T; Korhonen, P; Pietinen, P; Virtamo, J | 1 |
2 other study(ies) available for 2,3-bis(3'-hydroxybenzyl)butyrolactone and Chronic Illness
| Article | Year |
|---|---|
Urinary lignans and inflammatory markers in the US National Health and Nutrition Examination Survey (NHANES) 1999-2004 and 2005-2008.
Topics: 4-Butyrolactone; Adult; Aged; Biomarkers; C-Reactive Protein; Chronic Disease; Cross-Sectional Studies; Female; Humans; Inflammation; Leukocyte Count; Lignans; Male; Middle Aged; Nutrition Surveys; United States | 2014 |
Use of oral antimicrobials decreases serum enterolactone concentration.
Topics: 4-Butyrolactone; Administration, Oral; Adult; Anti-Bacterial Agents; Biomarkers; Chronic Disease; Cross-Sectional Studies; Digestive System; Female; Humans; Lignans; Middle Aged; Risk Factors | 2002 |